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Abstract
Objective: This comparative study was aimed at determining the effectiveness of oral Misoprostol compared with 
intravenous Ergometrine and intravenous Oxytocin in reducing vaginal bleeding following surgical evacuation for first 
trimester abortions.
Materials and Methods: This was a single-blind placebo-controlled study in which patients with first trimester 
uncomplicated abortions were divided into three groups using computer-generated randomization table. The first group 
was administered oral Misoprostol, the second group had intravenous Ergometrine, and the third group was administered 
intravenous Oxytocin. The uterotonic agents were administered before the surgical evacuation was carried out.
Results: There was statistically significant reduction in blood loss after the evacuation in the Misoprostol group (P < 0.000). 
There was also significant reduction in the number of days of bleeding in the Misoprostol group (2.00 ± 0.86) compared 
with 4.43 ± 0.92 and 4.64 ± 1.06 days in the Ergometrine and Oxytocin groups, respectively (P < 0.000). There were, 
however, more gastrointestinal side effects in the Misoprostol and Ergometrine groups (60.7% and 57.1%, respectively) 
compared with the Oxytocin group.
Conclusion: Oral Misoprostol appeared to demonstrate superior efficacy in reducing uterine bleeding after surgical 
evacuation, compared to the other commonly used uterotonic agents.
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Introduction
Abortion is a common complication of pregnancy and may 
either be spontaneous or induced. It is difficult to estimate 
the precise number of abortions due to underreporting, 
especially in developing countries. Spontaneous abortion is 
said to occur in about one‑fifth of pregnancies, an estimate 
based on hospital data.[1] Induced abortion also is difficult to 
estimate, particularly in countries with restrictive abortion 
laws such as in Nigeria and other countries in Africa. 
Induced abortion is underreported because it is criminalized 
in many countries. The high incidence of induced abortion 
is partly due to the low contraceptive prevalence, and 
as such, many unwanted pregnancies are often aborted 
and by unsafe methods. According to the World Health 
Organization (WHO), annually about 79 million unintended 
pregnancies, excluding miscarriages, occur worldwide.[2]
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Irrespective of the type of abortion, one of the commonest 
complications seen is persistent bleeding which is often 
due to the retained products of conception.[3] In fact, 
complications from abortion are common in Nigeria 
as over half of the women interviewed in a survey 
reported that they had suffered complications following 
abortions.[2] Complications from abortions resulted in the 
death of over 3000 women annually in Nigeria.[2]
To prevent persistent uterine bleeding after abortion, 
evacuation of the retained products of conception is usually 
carried out. This may be medical or surgical evacuation. 
After surgical evacuation of the retained products of 
conception following abortions, uterotonic agents such as 
Oxytocin and Ergometrine have traditionally been used 
to control uterine bleeding. In fact, the two uterotonic 
agents were the ones recommended by the Nigerian Federal 
Ministry of Health.[4]
Misoprostol, a synthetic prostaglandin E1 analogue, has 
been extensively used for cervical ripening prior to the 
induction of labor and even to induce labor and for the 
control of postpartum hemorrhage.[5‑9] Its use to control 
uterine bleeding after surgical evacuation of the uterus 
following first trimester abortion has not been widely studied 
in our environment.
Objectives of the study
The objectives of this comparative study are to compare 
the safety, tolerability, and clinical effectiveness of oral 
Misoprostol, intravenous Oxytocin, and intravenous 
Ergometrine in the management of uterine bleeding after 
surgical evacuation of first trimester abortion.
Materials and Methods
This was a single‑blind placebo‑controlled study. Approval 
for the study was obtained from the Ethics and Research 
Committee of the Obafemi Awolowo University Teaching 
Hospitals Complex. A total of 84 women who had missed 
abortion, inevitable or incomplete spontaneous abortion, 
and induced abortion without sepsis or organ perforation 
between 6 and 12 weeks of pregnancy were randomized 
into one of three arms: Oral Misoprostol or intravenous 
Oxytocin or intravenous Ergometrine. Excluded from the 
study were hemodynamically unstable patients, patients 
with septic abortion, and those with glaucoma or with 
known hypersensitivity to the three agents. Patients with 
hypertension and women who refused to give consent were 
also excluded from the study.
Each woman had adequate pre‑operative counseling and 
evaluation. Informed consent was obtained from each 
woman. The women were randomized into each arm of 
the study by computer‑generated table of random numbers.
Patients in each arm were administered the following 
according to the group:
Group 1: Oral Misoprostol 400 µg
Group 2: Intravenous Ergometrine 0.5 mg
Group 3: Intravenous Oxytocin 10 IU.
Women in Group 1 (oral Misoprostol) had 1 ml of normal 
saline administered intravenously as placebo, while the 
women in the Oxytocin and Ergometrine arms of the study 
were administered two lactose tablets as placebo.
Each patient was asked to empty her bladder and was 
placed in lithotomy position. The vagina, vulva, pubis, 
perineum, and inner aspects of the thighs were cleaned 
with chlorhexidine solution and sterile drapes were applied. 
Bimanual pelvic examination was done and the findings 
were noted. A Cusco’s speculum was introduced to retract 
the vaginal walls, thereby exposing the cervix. The anterior 
lip of the cervix was held with a sponge holding forceps, 
gentle downward traction applied, and the area between 
the smooth cervical epithelium and the vaginal epithelium 
was identified. A 3.5‑cm, 22‑G needle mounted on a 
10 ml syringe containing 0.5% lignocaine solution without 
adrenaline was used to inject 2 ml of the anesthetic solution 
just under the epithelium not deeper than 3 mm at 2, 5, 7, 
and 10 O’clock positions. At the conclusion of the set of 
injections, 2 min was allowed for the anesthetic agent to show 
its effect. An appropriate sized suction cannula was selected 
and introduced into the uterine cavity with uterine sounding 
done to determine its depth. This was then connected to the 
Manual Vacuum Aspiration syringe after a vacuum had been 
created in it. The vacuum was released and the products of 
conception were evacuated by a gentle rotary and in and 
out motion of the cannula until gritty sensation was felt and 
foamy blood came out of the uterine cavity. An appropriate 
Oxytocin agent was then administered. Weighed sterile 
pads were placed over the perineum after the procedure. All 
products were then sent for histopathologic examination.
Blood loss from each patient was determined within the 
first 6 h postoperatively using gravimetric methods with 
a digital weighing scale Model: Adventurer Pro AV313C 
manufactured by Ohaus Corporation, Pine Brook, NJ, 
USA with standardized sterile fixed‑sized gauze pads of size 
10 × 10 cm of known weight in grams, which was applied as 
vaginal packs immediately after the procedure and removed 
6 h later and re‑weighed in grams. This gave the amount of 
blood loss in milliliters. The patients were discharged home 
within 24 h after the surgical evacuation and were seen 
within 1 week after discharge at the outpatient clinic to 
determine if there were any complications and to determine 
the duration of bleeding. Women who could not attend the 
outpatient clinic were followed up by telephone calls.
Information obtained at the end of the study was processed 
by Statistical Package for Social Science (SPSS) version 17. 
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Descriptive statistics such as means, frequencies, and 
proportions were used to summarize variables depending 
on the variable type. The mean estimated blood loss and 
duration of bleeding were compared between the three study 
groups using the one‑way analysis of variance (ANOVA) 
and the level of significance was set at 0.05.
Results
There was statistically significant reduction in the mean 
volume of blood loss after the evacuation in the Misoprostol 
group with mean blood loss of 29.3  ± 4.0 ml, compared 
with a mean loss of 38.5  ± 5.2 ml and 34.3  ± 6.4 ml 
in the Ergometrine group and the Oxytocin group, 
respectively (P < 0.05) Table 1. There was also a significant 
reduction in the number of days of vaginal bleeding in 
the Misoprostol group (2.00 ± 0.86 days) compared with 
4.43 ± 0.92 and 4.64 ± 1.06 days in the Ergometrine and 
Oxytocin groups, respectively (P < 0.05) Table 2.
There was also a positive correlation between the gestational 
age and amount of bleeding (P  = 0.02), but there was 
none between gestational age and the number of days of 
bleeding (P = 0.187).
Gastrointestinal side effects were the most common side 
effects, and these were more in patients in the Misoprostol 
group [17 (60.7%)] compared with 16 (57.1%) and 5 
(17.9%) in the Ergometrine and Oxytocin arms, respectively. 
This was statistically significant (P < 0.001).
Discussion
The demographic characteristics of patients in each arm of 
the study as well as the indications for surgical evacuation 
were not statistically different [Tables 3 and 4]. The blood 
loss within the first 6 hours after surgical evacuation was 
less in the Misoprostol group. In a similar study carried out 
at the Women Health Centre, Assiut University, Egypt, by 
Shokry et al., oral Misoprostol was effective in reducing 
the prevalence and amount of vaginal bleeding after 
surgical evacuation for first trimester abortion, compared 
with the group that had no Misoprostol.[10] Similar results 
were obtained in this study despite using lower dosage of 
Misoprostol compared to the Egyptian study. Also, unlike 
the Egyptian study, this study compares the efficacy of oral 
Misoprostol with that of other uterotonics agents, and to 
minimize cost, a single oral dose of 400 µg of Misoprostol 
was used.
One of the reasons for persistent uterine bleeding after 
abortion is the retained products of conception.[3] Stronger 
uterine contraction induced by Misoprostol may lead to 
complete uterine evacuation, thereby leading to reduced 
Table 1: Comaprison of volume of blood loss post‑evacuation by one‑way ANOVA (in ml)
n Mean Std. deviation Std. error 95% confidence interval for 
mean
Minimum Maximum
Lower bound Upper bound
Misoprostol 28 29.2500 4.03343 0.76225 27.6860 30.8140 21.00 34.00
Ergometrine 28 38.4643 5.18175 0.97926 36.4550 40.4736 31.00 48.00
Oxytocin 28 34.3214 6.41210 1.21177 31.8351 36.8078 21.00 49.00
Total 84 34.0119 6.46304 0.70518 32.6093 35.4145 21.00 49.00
F statistics=21.238 and P<0.000
Table 2: Comparison of duration of uterine bleeding post‑evacuation by one‑way ANOVA (in days)
n Mean Std. deviation Std. error 95% confidence interval for 
mean
Minimum Maximum
Lower bound Upper bound
Misoprostol 28 2.0000 0.86066 0.16265 1.6663 2.3337 1.00 4.00
Ergometrine 28 4.4286 0.92009 0.17388 4.0718 4.7853 2.00 6.00
Oxytocin 28 4.6429 1.06160 0.20062 4.2312 5.0545 3.00 7.00
Total 84 3.6905 1.52865 0.16679 3.3587 4.0222 1.00 7.00
F statistics=66.684; P value=0.000
Table 3: Demographic characteristics of the study groups
Demographic data Misoprostol group Ergometrine group Oxytocin group P value Outcome
Age (years) 26.5±2.9 26.3±3.6 27.1±5.3 0.71 Not significant
Gestational age (weeks) 9.6±1.4 8.9±2.3 9.1±1.4 0.23 Not significant
Body mass index (kg/m2) 24.3±3.5 25.7±3.4 25.4±4.2 0.33 Not significant
Gravidity 2.7±1.3 2.4±1.2 2.9±1.5 0.49 Not significant
Parity 1.8±1.2 1.4±1.2 1.9±1.6 0.36 Not significant
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bleeding and risk of uterine infection. Though the other 
uterotonic agents used in this study (Ergometrine and 
Oxytocin) also induce strong uterine contractions, they 
may be less potent because they need stringent storage 
conditions like constant refrigeration which may not be 
readily available in developing countries, especially in the 
rural areas where majority of the populace resides with little 
access to constant power supply. Oxytocin and Ergometrine 
lose their potencies when exposed to direct sunlight and 
due to poor storage conditions.[7] The WHO has in fact 
drawn attention of practitioners in the developing countries 
to these shortcomings.[8] Another major disadvantage in 
the use of both Oxytocin and Ergometrine is that they 
are administered parenterally unlike Misoprostol which is 
effective when administered orally.
Conclusion
This study showed that a single oral dose of Misoprostol is 
better than parenteral administration of either Oxytocin 
or Ergometrine in reducing the amount and duration of 
vaginal bleeding after surgical evacuation of a first trimester 
abortion. Oral Misoprostol was, however, associated with 
more gastrointestinal side effects.
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Table 4: Indication for surgical evacuation in the 
three groups
Clinical data: Indication Total
Incomplete Missed Inevitable
Study group
Misoprostol 25 2 1 28
Ergometrine 25 1 2 28
Oxytocin 26 1 1 28
Total 76 4 4 84
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